Nonpenetrating XXXX with the use of adjunctive @entity1138 .

@entity1 @entity1538 @entity548 @entity1138 @entity726 @entity1139 @entity2632 @entity2790 @entity5891
BACKGROUND AND OBJECTIVE: To determine whether adjunctive use of @entity1138 ( @entity1139 ) would increase the success rate of primary nonpenetrating @entity2632 with collagen implant. @entity1 AND METHODS: Twenty-six @entity1 (26 eyes) with primary @entity1538 uncontrolled with maximally tolerated medical therapy were randomly assigned to undergo nonpenetrating @entity2632 and collagen implant, either with (13 eyes) or without (13 eyes) 0.3 mg/mL of adjunctive @entity1139 for 3 minutes. @entity2790 ( @entity2790 ), number of @entity726 medications, and visual acuity were assessed before and 12 and 24 months after surgery. RESULTS: The mean age of the study @entity1 was similar in both groups ( @entity1139 = 68.1 +/- 8 years, control = 65.8 +/- 6.8 years). At the 12- and 24-month follow-up visits, the mean @entity2790 with or without medications was lower in the @entity1139 group than in the control group (15.6 +/- 3.5 vs 17.2 +/- 3.9 mm Hg at 12 months and 15.8 +/- 5.6 vs 17.8 +/- 2.8 mm Hg at 24 months, respectively). The @entity2790 with or without medications significantly decreased after surgery in both groups (P < .05). Twelve months after surgery, the @entity2790 decreased by 48% in the @entity1139 group and by 35% in the control group. At the end of follow-up (24 months), the @entity2790 decreased by 48% in the @entity1139 group and by 32% in the control group (P = .01). The mean number of @entity726 medications decreased after surgery, there was no significant difference in complications ( @entity5891 and @entity548 ), and visual acuity was unchanged throughout the study in both groups. CONCLUSION: The use of @entity1139 in nonpenetrating @entity2632 with collagen implant is safe and improves surgical results.
